- Core One Labs subsidiary Akome Biotech Ltd. is developing a psychedelic drug formulation to reduce neurological damage resulting from ischemic strokes
- Akome’s psychedelic drug formulation is comprised of the psychedelic compound N,N-dimethyltryptamine (DMT) and a plant bioactive
- Akome is in the process of identifying Contract Research Organizations (CROs) to work with
- Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market
- Core One Labs Inc. (COOL) opened trading at C$0.69 per share
Core One Labs (COOL) subsidiary Akome Biotech Ltd. is developing a psychedelic drug formulation to reduce neurological damage resulting from ischemic strokes.
Akome’s psychedelic drug formulation, also known as AKO001, is comprised of the psychedelic compound N,N-dimethyltryptamine (DMT) and a plant bioactive.
A provisional matter of composition patent application for AKO001 has been filed with the United States Patent and Trademark Office.
Ischemia is a condition in which the blood vessels become blocked, and blood flow is stopped or reduced. When blood flow is diminished to a body part, that body part also does not receive adequate oxygen. Most strokes are ischemic by nature, and blood flow through the artery that supplies oxygen-rich blood to the brain becomes blocked, and brain cells begin to die.
Ischemic stroke is the 3rd most common cause of death and the leading cause of disability worldwide in adults. The World Health Organization estimates that 17.9 million people die from stroke worldwide each year.
Akome’s specifically chosen plant bioactive and DMT are an ideal combination of compounds for mitigating the neurological damage caused by ischemic strokes.
The bioactive shows evidence of promoting positive apoptotic processes, and the DMT induces the formation of glial cells (a type of supportive cell in the central nervous system involved in regulating homeostasis and providing protection to the functioning of the nervous system). These complimentary functions could theoretically optimize in vivo replacement of neurons after a neural injury, such as a stroke.
Akome is in the process of identifying Contract Research Organizations (CROs) to work with as it sets the development process of its novel AKO001 psychedelic drug formulation and its advancement for stroke treatment.
“Our goal with the development of AKO001 is to reduce the damage from the number of life long disabling symptoms that can occur after experiencing a stroke. We look forward to continued development on this front and providing updates to the medical community on our progress.” stated Joel Shacker CEO of Core One Labs.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.
Core One has developed a patent-pending thin film oral strip that dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability.
Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.
Core One Labs Inc. (COOL) opened trading at C$0.69 per share.
